Swiss BioTech platform NUCLIDIUM raises €84 million for the analysis and therapy of most cancers

Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical firm growing a proprietary copper-based theranostic platform, at present introduced the profitable closing of its Sequence B financing spherical, elevating €84 million.

The spherical was led by Kurma Development Alternatives Fund, Angelini Ventures, Wellington Companions, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Local weather Fonds (DTCF), Bayern Kapital, Vives Companions, Eurazeo, NRW.BANK and HighLight Capital, in addition to current buyers.

“NUCLIDIUM is getting into the following medical phases with its lead compounds to diagnose and deal with metastatic prostate, neuroendocrine tumors and breast most cancers,” mentioned Leila Jaafar, PhD, CEO and Co-Founding father of NUCLIDIUM. “Our copper-based radiotheranostics are developed for seamless use in hospital workflows, care supply and waste administration, making these therapies extra accessible worldwide. Our groundbreaking subsequent era copper theranostic platform additionally permits us to quickly develop new targets throughout a wider vary of cancers, notably these extremely related to ladies’s well being.”

Based in 2017, NUCLIDIUM AG is a clinical-stage BioTech firm innovating the event of next-generation copper-based radiopharmaceuticals for the analysis and therapy of most cancers.

Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is making a differentiated platform with the potential to beat current limitations in radiotheranostics.

NUCLIDIUM says they’re dedicated to increasing the attain and efficacy of radiotheranostics, together with addressing important unmet medical wants in oncology and ladies’s well being.

NUCLIDIUM’s differentiated platform hyperlinks tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to handle present limitations in radiotheranostics, resembling suboptimal medical efficacy and sophisticated manufacturing.

“VIVES Companions is thrilled to be among the many contributors on this important fundraising spherical,” mentioned Sandra Schoors, companion at VIVES Companions. “Now we have a powerful perception within the potential of Nuclidium’s copper-based platform as a novel radiotheranostic. The corporate’s progressive method tackles the important limitations in present radiopharmaceutical strategies, paving the way in which for simpler and accessible most cancers remedies. We’re excited to help this groundbreaking expertise and stay up for its transformative affect on healthcare.”

Diagnostic outcomes from preliminary medical trials in these indications present superior lesion detection and better tumor-to-background ratios in contrast with clinically authorised tracers. Preliminary information have been lately offered at SNMMI 2025 by Dr Gary Ulaner, MD, PhD highlighting a positive security profile and doubtlessly improved imaging efficiency of ⁶¹Cu-NuriPro™ in comparison with present PET imaging requirements, suggesting robust medical promise and broader potential for ⁶¹Cu/⁶⁷Cu theranostic pairing.

Early therapeutic information from the 2 lead compounds, NuriPro™ and TraceNET™, reportedly present robust tumor-to-background ratios in metastatic prostate most cancers and neuroendocrine tumors together with breast most cancers.

“This important Sequence B financing displays the boldness of our buyers in NUCLIDIUM’s imaginative and prescient and the transformative potential for the diagnostic and therapeutic business in oncology and nuclear drugs,” mentioned Tony Rosenberg, Chairman of the NUCLIDIUM Board. “With this backing, we’re positioned to speed up medical improvement, broaden affected person entry globally, and reinforce our dedication to innovation in precision oncology. I’m delighted to welcome our new Board and advisory members, whose deep experience will additional strengthen NUCLIDIUM’s management in radiopharmaceuticals.”

With this financing, NUCLIDIUM will proceed increasing its worldwide manufacturing and manufacturing community for diagnostics and therapeutics, rising its worldwide staff, and strengthening strategic collaborations with hospitals and educational centres, initially throughout Europe and North America.

The proceeds may even be used to advance the medical improvement of NUCLIDIUM’s Copper-61/Copper-67 (⁶¹Cu/⁶⁷Cu) theranostic pipeline throughout a number of oncology indications.

At the side of the financing spherical, Daniel Parera, MD, Associate at Kurma Companions, Regina Hodits, PhD, Managing Director at Angelini Ventures, and Liliana Nordbakk, Associate Life Sciences at Neva SGR, will be part of NUCLIDIUM’s Board of Administrators.

“NUCLIDIUM’s platform stands out in a quickly evolving subject and can change how radiotheranostic care is delivered. This funding displays our robust conviction in the way forward for precision drugs and our perception in NUCLIDIUM’s potential to scale as a next-generation firm – an ambition shared throughout a powerful European syndicate,” added Daniel Parera, MD, Associate at Kurma Companions, Regina Hodits, PhD, Managing Director at Angelini Ventures, and Liliana Nordbakk, Associate Life Sciences at Neva SGR for all taking part buyers.